Read by QxMD icon Read

corticosteroid alopecia areata

Ana Batalla, Ángeles Flórez, Teresa Abalde, Hugo Vázquez-Veiga
There are few studies about systemic treatment in severe cases of alopecia areata (AA), especially in the pediatric population. Although there is more experience with systemic corticosteroids, recent reports have suggested methotrexate (MTX) as an alternative treatment, with a relatively good outcome. We describe three cases of AA in children treated with MTX, two of them with successful results.
October 2016: International Journal of Trichology
J H Chong, A Taïeb, F Morice-Picard, A S Dutkiewicz, C Léauté-Labrèze, F Boralevi
Alopecia areata (AA) in childhood can run a chronic course and worsen over time(1). Spontaneous hair regrowth is rarely appreciated in chronic severe AA(2-4). Our centre described the ineffective use of high dose pulsed corticosteroid therapy (HDPCT) in the long term(1). Methotrexate (MTX) as a maintenance therapy following HDPCT showed some success in adults(5). Although the evidence for using either drug individually was weak(6), the combination of using both was not well studied. This article is protected by copyright...
April 20, 2017: Journal of the European Academy of Dermatology and Venereology: JEADV
Oscar Muñoz Moreno-Arrones, Sergio Vañó-Galván
We present a 24-year-old woman that had received a diagnosis of alopecia areata in the past and was treated with topical 19 corticosteroids with little improvement. Instead, the patient exhibited bitemporal alopecia of one year of evolution related to 20 traction alopecia. Traction alopecia is characterized by localized hair loss related to persistent excessive traction. Although it is 21 initially a reversible condition, if this excessive traction is not removed permanent alopecia may develop.
September 15, 2016: Dermatology Online Journal
Karin Jahn-Bassler, Wolfgang Michael Bauer, Franz Karlhofer, Matthias G Vossen, Georg Stingl
BACKGROUND: Given the limited number of therapeutic options, severe childhood alopecia areata (AA) poses a clinical challenge. The best and most rapid response rates can be achieved with high-dose systemic corticosteroids, however, relapse following treatment discontinuation is inevitable. Due to systemic side effects, long-term high-dose corticosteroid regimens are not feasible. Following initial pulse therapy, continuation of corticosteroid therapy at a dose below the Cushing threshold might be able to suppress disease activity without causing severe side effects...
January 2017: Journal der Deutschen Dermatologischen Gesellschaft, Journal of the German Society of Dermatology: JDDG
Sineida Berbert Ferreira, Morton Scheinberg, Denise Steiner, Tatiana Steiner, Gustavo Longhi Bedin, Rachel Berbert Ferreira
Alopecia areata (AA) is a chronic, autoimmune disease. The main symptom is massive hair loss, localized or diffuse, in the scalp and the whole body. However, nails may also be involved, and brittleness, fragility and pitting can be signs of nail dystrophy in AA patients. Here, we report the case of a male patient with AA refractory to various treatments, including oral, topical and intralesional corticosteroids, immunosuppressants, cyclosporin and PUVA (oxoralen plus ultraviolet light), all interrupted due to side effects...
September 2016: Case Reports in Dermatology
Juliany Estefan, Marcia Ribeiro, Eliane Abad, Simone Saintive, Marcia Ramos-E-Silva
The prognosis of alopecia areata is better in cases with single and small lesions, and the variability of the extension of the disease is one of the criteria for the choice of treatment modality. Several medications have been described in the literature for the treatment of alopecia areata, including corticosteroids, minoxidil, and diphencyprone. The authors review treatments for alopecia areata.
2016: Skinmed
Stephanie Mlacker, Adam Souhail Aldahan, Brian James Simmons, Vidhi Shah, Colin Andrew McNamara, Sahal Samarkandy, Keyvan Nouri
Alopecia areata is a form of non-scarring alopecia that results from a hyperactive immune response of T cells against hair follicles. Many patients with visible hair loss experience psychological and emotional distress, as a result of their cosmetic disfigurement, and frequently seek treatment. However, existing treatment methods, such as corticosteroids, topical irritants, sensitizing agents, immunosuppressants, and psoralen plus ultraviolet light A, may result in various adverse effects and often lack efficacy...
April 2017: Journal of Cosmetic and Laser Therapy: Official Publication of the European Society for Laser Dermatology
Aditya K Gupta, Jessie Carviel, William Abramovits
Alopecia areata (AA) is non-scarring hair loss resulting from an autoimmune disorder. Severity varies from patchy hair loss that often spontaneously resolves to severe and chronic cases that can progress to total loss of scalp and body hair. Many treatments are available; however, the efficacy of these treatments has not been confirmed, especially in severe cases, and relapse rates are high. First-line treatment often includes corticosteroids such as intralesional or topical steroids for mild cases and systemic steroids or topical immunotherapy with diphenylcyclopropenone or squaric acid dibutylester in severe cases...
February 2017: American Journal of Clinical Dermatology
Sapna M Amin, Timothy Tan, Joan Guitart, Maria Colavincenzo, Pedram Gerami, Pedram Yazdan
A 33-year-old female with a 7-year history of CD8-positive hypopigmented mycosis fungoides (MF) involving the trunk and extremities presented with a large well-defined alopecic patch on her frontal scalp. Clinically, this area resembled alopecia areata (AA) and was without hypopigmentation or erythema. A scalp biopsy revealed a non-scarring inflammatory alopecia and a superficial band-like atypical lymphoid infiltrate with prominent epidermotropism. Atypical, predominately CD8-positive lymphocytes were seen surrounding and infiltrating the bulb portion of several hair follicles...
December 2016: Journal of Cutaneous Pathology
Maedeh Rezghi, Shirin Fahimi, Sara Zakerin
BACKGROUND: Alopecia areata (AA) is a common immune-mediated hair loss disorder. AA has a reported incidence of 0.1-0.2% with a lifetime risk of 1.7%. Histologically, AA is characterized by the accumulation of mononuclear cells around the bulb of the affected hair follicles. Corticosteroids are the most popular drugs for the treatment of this disease. Despite its high prevalence, currently available treatments are mostly unsatisfactory and inefficient for the more chronic and severe types of the AA...
May 2016: Iranian Journal of Medical Sciences
U Wollina, J Hercogovấ, M Fioranelli, S Gianfaldoni, A A Chokoeva, G Tchernev, M Tirant, F Novotny, M G Roccia, G K Maximov, K França, T Lotti
UNLABELLED: Alopecia areata is a highly prevalent organ restricted autoimmune disorder that leads to disfiguring hair loss and is thought to involve a T cell–mediated response to the hair follicle. The treatment of alopecia areata is often problematic and very frustrating, partly due to the unknown aetiology of the condition. The aim of this study was to evaluate the efficacy and tolerability of complementary medicine, Dr. Michaels® product family, in the treatment of alopecia areata...
April 2016: Journal of Biological Regulators and Homeostatic Agents
Jimyung Seo, Young In Lee, Shinwon Hwang, Zhenlong Zheng, Do Young Kim
Severe alopecia areata (AA) can have an unpredictable clinical course and become refractory to contact immunotherapy. Novel treatment options include low-dose interleukin-2 and Janus kinase inhibitors; however, these treatments are still under investigation. Therefore, we evaluated the efficacy and safety of intramuscular (i.m.) triamcinolone acetonide (TAC) as a rescue therapy for refractory AA. We retrospectively analysed efficacy, adverse effects and relapse rate of i.m. TAC monthly in 27 patients with refractory AA...
July 23, 2016: Journal of Dermatology
Alvin W Li, Richard J Antaya
Alopecia areata (AA) is a genetic and immune-mediated disease that targets anagen hair follicles. Despite limited evidence supporting the efficacy of corticosteroid treatments, they are often prescribed as first-line therapy because of their favorable safety profile. Prostaglandin analogues are currently being studied as an alternate therapy for scalp AA in adults. Herein we present a case of steroid-resistant multifocal AA that was successfully treated with topical bimatoprost.
September 2016: Pediatric Dermatology
Jillian F Rork, Mehdi Rashighi, John E Harris
PURPOSE OF REVIEW: Vitiligo and alopecia areata are common, disfiguring skin diseases. Treatment options are limited and include nontargeted approaches, such as corticosteroids, topical calcineurin inhibitors, narrow band ultraviolet B phototherapy, and other immune-modifying agents. The purpose of this article is to review shared, novel mechanisms between vitiligo and alopecia areata, as well as discuss how they inform the development of future targeted treatments. RECENT FINDINGS: Vitiligo and alopecia areata are both autoimmune diseases, and striking similarities in pathogenesis have been identified at the level of both the innate and adaptive immune system...
August 2016: Current Opinion in Pediatrics
Takashi Yoshimasu, Nobuo Kanazawa, Yuki Yamamoto, Fukumi Furukawa
Various systemic corticosteroid therapies are used for alopecia areata (AA). Pulse therapy using methylprednisolone is a treatment approach for AA. The efficacy of multiple courses of pulse therapy for various severities of AA was evaluated. AA patients with less than 50% hair loss, less than or equal to 6 months after AA onset, needed 1.9 courses of pulse therapy for vellus hair to develop. On the other hand, AA patients with more than 50% hair loss, less than 6 months after AA onset, needed more courses of pulse therapy for vellus hair to develop...
September 2016: Journal of Dermatology
Jeff Donovan
No abstract text is available yet for this article.
September 2015: JAAD Case Reports
Firas Constantin Kreeshan, Philip Hampton
BACKGROUND: Hypersensitivity reactions to intralesional corticosteroids are very rare and have been infrequently reported. Patch testing is considered the gold standard for diagnosing contact allergic dermatitis. However, intradermal testing is thought to be more accurate and sensitive in selected cases. MAIN OBSERVATION: We describe a case of a delayed hypersensitivity reaction to intralesional triamcinolone acetonide following the treatment of alopecia areata...
December 31, 2015: Journal of Dermatological Case Reports
Mehdi Amirnia, Seyed-Sajjad Mahmoudi, Farid Karkon-Shayan, Hossein Alikhah, Reza Piri, Mohammad Naghavi-Behzad, Mohammad-Reza Ranjkesh
BACKGROUND AND OBJECTIVES: Alopecia areata (AA) is a common, non-scarring type of hair loss, affecting approximately 2.1% of the population, many modality of treatment recommended like steroid injection, topical Immunotherapy and several systemic therapies. The aim of this study was to compare intralesional steroid injection and cryotherapyoutcomes in AA. MATERIALS AND METHODS: In an analytical-descriptive study, 120 AA patients treated with intralesionalsteroid injection and 120 AA patients treated with cryotherapy were randomly selected...
July 2015: Nigerian Medical Journal: Journal of the Nigeria Medical Association
Delphine Anuset, Geraldine Perceau, Philippe Bernard, Ziad Reguiai
BACKGROUND: In severe alopecia areata (AA), spontaneous recovery is unlikely, and treatment is not standardized. OBJECTIVE: To evaluate the efficacy and safety of methotrexate (MTX) used alone or combined with low- to moderate-dose oral corticosteroids (OC) for treating severe AA (totalis, universalis and severe multifocal). METHODS: Retrospective monocentric study of all consecutive patients receiving this treatment between 2006 and 2012...
2016: Dermatology: International Journal for Clinical and Investigative Dermatology
In Kwon Yeo, Eun Jung Ko, Yeon A No, Ee Seok Lim, Kui Young Park, Kapsok Li, Beom Joon Kim, Seong Jun Seo, Myeung Nam Kim, Chang Kwun Hong
BACKGROUND: Severe alopecia areata (AA) is resistant to conventional treatment. Although systemic oral corticosteroids are an effective treatment for patients with severe AA, those drugs have many adverse effects. Corticosteroid pulse therapy has been introduced to increase therapeutic effects and reduce adverse effects. However, the treatment modality in severe AA is still controversial. OBJECTIVE: To evaluate the effectiveness of corticosteroid pulse therapy in patients with severe AA compared with treatment with oral cyclosporine with corticosteroid...
December 2015: Annals of Dermatology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"